Abstract

This presentation will discuss whether there is a place for in-vitro maturation of oocytes (IVM) in Australia, in contrast to employing standard ovarian stimulation for all our patients. Particularly, when we are fortunate to have such excellent tools to minimise the risk of ovarian hyperstimulation syndrome (OHSS), such as; accurate drug dosing with follicular stimulating hormone, the use of antagonists for pituitary down-regulation in conjunction with an agonist trigger for follicular maturation. With the recourse to adjuvant treatments such as metformin and cabergoline to reduce the risk of developing OHSS, along with the option to cryopreserve all embryos developed. The presentation will conclude that it has a place, although the indications are perhaps rather limited.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call